Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian Rheumatology Association Database (ARAD) prospective cohort study

Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian Rheumatology Association Database (ARAD) prospective cohort study

Abstract Background Tumour necrosis factor inhibitor (TNFi) therapy has been available for rheumatoid arthritis (RA) patients for several decades but data on the long-term risk of malignancy associated with its use is limited. Our aims were to assess malignancy risk in a cohort of Australian RA pati...

Full description

Bibliographic Details
Main Authors: Margaret P. Staples, Lyn March, Catherine Hill, Marissa Lassere, Rachelle Buchbinder
Format: Article
Language:English
Published: BMC 2019-01-01
Series:BMC Rheumatology
Subjects:
Rheumatoid arthritis
Malignancy
Tumour necrosis factor
Biologic therapy
Online Access:http://link.springer.com/article/10.1186/s41927-018-0050-7

Internet

http://link.springer.com/article/10.1186/s41927-018-0050-7

Similar Items